These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10229966)

  • 61. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
    Müller T; Kuhn W
    Eur J Clin Pharmacol; 2006 Jun; 62(6):447-50. PubMed ID: 16758261
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Modern therapeutic possibilities in Parkinson disease].
    Ludin HP
    Schweiz Med Wochenschr; 1999 May; 129(19):741-7. PubMed ID: 10407949
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Müller T
    Drugs; 2015 Feb; 75(2):157-74. PubMed ID: 25559423
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment.
    Espinoza S; Manago F; Leo D; Sotnikova TD; Gainetdinov RR
    CNS Neurol Disord Drug Targets; 2012 May; 11(3):251-63. PubMed ID: 22483291
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.
    Luer MS
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):169S-79S. PubMed ID: 10555945
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Catechol-O-methyltransferase inhibitors: new options for Parkinson's disease.
    Leicht MJ; Mitchell SD
    S D J Med; 1999 Aug; 52(8):295-7. PubMed ID: 10453205
    [No Abstract]   [Full Text] [Related]  

  • 68. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects.
    Tuunainen J; Sjöstedt N; Vahteristo M; Ellmén J; Kuoppamäki M; Rouru J; Yliperttula M
    Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):23-34. PubMed ID: 36309950
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease.
    Tan EK; Cheah SY; Fook-Chong S; Yew K; Chandran VR; Lum SY; Yi Z
    Am J Med Genet B Neuropsychiatr Genet; 2005 Aug; 137B(1):1-4. PubMed ID: 15965967
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease.
    Limousin P; Pollak P; Gervason-Tournier CL; Hommel M; Perret JE
    Lancet; 1993 Jun; 341(8860):1605. PubMed ID: 8099689
    [No Abstract]   [Full Text] [Related]  

  • 72. [Recent advances in Parkinson disease].
    Litvan I
    Rev Neurol; 1999 Jul 16-31; 29(2):139-45. PubMed ID: 10528328
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.
    Torkaman-Boutorabi A; Shahidi GA; Choopani S; Rezvani M; Pourkosary K; Golkar M; Zarrindast MR
    Acta Neurobiol Exp (Wars); 2012; 72(3):272-82. PubMed ID: 23093014
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone.
    Jenner P; Rocha JF; Ferreira JJ; Rascol O; Soares-da-Silva P
    Expert Rev Neurother; 2021 Sep; 21(9):1019-1033. PubMed ID: 34525893
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical pharmacology review of opicapone for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Ferreira JJ
    Neurodegener Dis Manag; 2016 Oct; 6(5):349-62. PubMed ID: 27599671
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Tolcapone: a different, effective approach to improving dopaminergic treatment in Parkinson's disease].
    Kulisevsky J
    Neurologia; 1998 Feb; 13(2):74-82. PubMed ID: 9578674
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Pharmacological treatments of Parkinson's disease].
    Nomoto M; Iwata S; Kaseda S
    Nihon Yakurigaku Zasshi; 2001 Feb; 117(2):111-22. PubMed ID: 11233302
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.
    Bonifácio MJ; Palma PN; Almeida L; Soares-da-Silva P
    CNS Drug Rev; 2007; 13(3):352-79. PubMed ID: 17894650
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Opicapone (Ongentys) - a COMT inhibitor for Parkinson's disease.
    Med Lett Drugs Ther; 2021 Jan; 63(1615):3-5. PubMed ID: 33646998
    [No Abstract]   [Full Text] [Related]  

  • 80. First COMT inhibitor approved for Parkinson's disease.
    Am J Health Syst Pharm; 1998 Mar; 55(6):524, 526. PubMed ID: 9544322
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.